Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2831825 | 0.95 | PDE2A (0.46) | PDE2AKMT2AADORA3HPGDHTT | |
| SCHEMBL1960594 | 0.93 | PDE2A (0.43) | PDE2AKMT2AADORA3HPGDHTT | |
| SCHEMBL1959212 | 0.91 | PDE2A (0.42) | PDE2AKMT2AADORA3HPGDHTT | |
| SCHEMBL1960096 | 0.91 | PDE2A (0.42) | PDE2AKMT2AADORA3HPGDHTT | |
| SCHEMBL7360012 | 0.91 | HPGD (0.47) | PDE2AKMT2AADORA3HPGD | |
| SCHEMBL7355845 | 0.91 | KMT2A (0.43) | PDE2AKMT2AADORA3HPGDHTT | |
| SCHEMBL1962754 | 0.90 | PDE2A (0.42) | PDE2AKMT2AADORA3HPGDHTT | |
| SCHEMBL7353463 | 0.90 | PDE2A (0.41) | PDE2AKMT2AADORA3RXFP1HPGD | |
| SCHEMBL7355722 | 0.90 | ADORA3 (0.48) | PDE2AKMT2AADORA3HPGD | |
| SCHEMBL1961437 | 0.87 | PDE2A (0.39) | PDE2AKMT2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179152-A1 | Novel use for PDE5 inhibitors | NYCOMED GMBH (DE) | 2010-07-15 | — | — | US | claimed |
| EP-1740183-B1 | NOVEL USE FOR PDE5 INHIBITORS | NYCOMED GMBH (DE) | 2009-10-14 | — | — | EP | claimed |
| US-20070185114-A1 | Novel use for pde5 inhibitors | ALTANA PHARMA AG (DE) | 2007-08-09 | — | — | US | claimed |
| US-20050107394-A1 | for the treatment of respiratory failure in patients showing a mismatch of pulmonary ventilation and pulmonary perfusion; e.g. 3-ethyl-8-[2-(4-morpholinylmethyl)benzylamino]-2,3-dihydro-1H-imidazo[4,5-g]quinazoline-2-thione | GHOFRANI ARDESCHIR (DE) | 2005-05-19 | — | — | US | claimed |
| EP-1461022-A2 | USE OF SELECTIVE PDE5 INHIBITORS FOR TREATING PARTIAL AND GLOBAL RESPIRATORY FAILURE | ALTANA Pharma AG (DE) | 2004-09-29 | — | — | EP | claimed |
| WO-2003051346-A2 | USE OF SELECTIVE PDE5 INHIBITORS FOR TREATING PARTIAL AND GLOBAL RESPIRATORY FAILURE | ALTANA PHARMA AG (DE) | 2003-06-26 | — | — | WO | claimed |
| EP-3267986-B1 | PDE5 INHIBITORS FOR USE IN REDUCING RENAL CYST SIZE AND/OR PREVENTING RENAL CYST GROWTH | UNIV INDIANA RES & TECH CORP (US) | 2022-09-14 | — | — | EP | disclosed |
| US-10456404-B2 | Targeting cGMP-related phosphodiesterases to reduce cyst formation in cystic kidney disease, and related materials and methods | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-10-29 | — | — | US | disclosed |
| US-20180078559-A1 | TARGETING cGMP-RELATED PHOSPHODIESTERASES TO REDUCE CYST FORMATION IN CYSTIC KIDNEY DISEASE, AND RELATED MATERIALS AND METHODS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY COPORATION (US) | 2018-03-22 | — | — | US | disclosed |
| EP-3267986-A1 | TARGETING cGMP-RELATED PHOSPHODIESTERASES TO REDUCE CYST FORMATION IN CYSTIC KIDNEY DISEASE, AND RELATED MATERIALS AND METHODS | Indiana University Research&Technology Corporation (US) | 2018-01-17 | — | — | EP | disclosed |
| WO-2016149218-A1 | TARGETING cGMP-RELATED PHOSPHODIESTERASES TO REDUCE CYST FORMATION IN CYSTIC KIDNEY DISEASE, AND RELATED MATERIALS AND METHODS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-09-22 | — | — | WO | disclosed |
| US-8278300-B2 | Use for PDE5 inhibitors | NYCOMED GMBH (DE) | 2012-10-02 | — | — | US | disclosed |
| US-8268785-B2 | Such as tadalafil or sildenafil; vitiligo; use in combination with Pimecrolimus, Tacrolimus, or Cyclosporin A | SWITCH BIOTECH AG (DE) | 2012-09-18 | — | — | US | disclosed |
| WO-2006018088-A1 | USE OF A PDE 5 INHIBITOR FOR TREATING AND PREVENTING HYPOPIGMENTARY DISORDERS | SWITCH BIOTECH AG (DE) | 2006-02-23 | — | — | WO | disclosed |
| WO-2005089766-A1 | NOVEL USE FOR PDE5 INHIBITORS | ALTANA PHARMA AG (DE) | 2005-09-29 | — | — | WO | disclosed |
| US-20050107394-A1 | for the treatment of respiratory failure in patients showing a mismatch of pulmonary ventilation and pulmonary perfusion; e.g. 3-ethyl-8-[2-(4-morpholinylmethyl)benzylamino]-2,3-dihydro-1H-imidazo[4,5-g]quinazoline-2-thione | GHOFRANI ARDESCHIR (DE) | 2005-05-19 | — | — | US | disclosed |
| EP-1461022-A2 | USE OF SELECTIVE PDE5 INHIBITORS FOR TREATING PARTIAL AND GLOBAL RESPIRATORY FAILURE | ALTANA Pharma AG (DE) | 2004-09-29 | — | — | EP | disclosed |
| WO-2003051346-A2 | USE OF SELECTIVE PDE5 INHIBITORS FOR TREATING PARTIAL AND GLOBAL RESPIRATORY FAILURE | ALTANA PHARMA AG (DE) | 2003-06-26 | — | — | WO | disclosed |
| EP-1107968-B1 | DIHYDRO-[1,2,3]TRIAZOLO-[4,5-D]PYRIMIDIN-7-ONE | BAYER AG (DE) | 2002-11-13 | — | — | EP | disclosed |
| US-6458796-B1 | METHOD OF TREATING CARDIOVASCULAR DISORDERS, THROMBOEMBOLIC DISORDERS AND ISCHAEMIAS, AND UROGENITAL SYSTEM DISORDERS, COMPRISING ADMINISTERING TO MAMMALS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-10-01 | — | — | US | disclosed |